Nationa

J&J sets the ball rolling to bring in its one-shot Covid-19 vaccine

PT Jyothi Datta Mumbai | Updated on April 10, 2021

The Johnson & Johnson vaccine has received the emergency use authorisation in the US in late February, with the WHO following close on its heels and giving similar approvals in mid-March.

American healthcare company Johnson & Johnson is in talks with the Government to initiate local trials to bring its Covid-19 vaccine to India. This would be a shot in the arm for the Covid-19 immunisation programme, as J&J’s is a single dose vaccine.

“We are in discussions with the Government of India with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals,”a J&J India spokesperson confirmed.

J&J has a local production tie-up with Bological E and the latest development was expected following the stated support from United States President Biden’s administration during the Quad meet last month.

The vaccine has received the emergency use authorisation in the US in late February, with the WHO following close on its heels and giving similar approvals in mid-March.

The vaccine requires standard storage and distribution conditions, but has been receiving much attention internationally, for more than just its one-shot convenience. The vaccine’s global trials were done even as the South African and Brazilian variants of the coronavirus were on the rise. Further, the vaccine’s late stage trials were done on a diverse population.

Published on April 09, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.